Skip to main content

Light, Metabolic Syndrome, and Alzheimer's Disease


This study will test the long-term effect of 24 weeks of a light treatment on cognition, sleep, and metabolism in people with mild cognitive impairment (MCI), mild Alzheimer's disease, or a related dementia.

Minimum Age Maximum Age Gender Healthy Volunteers
55 Years N/A All No
April 1, 2019
September 1, 2022

  • MCI, mild Alzheimer's disease , or related dementia (MMSE score of >19 or Clinical Dementia Rating of 0.5 or 1)
  • Sleep disturbance
  • Live at home

  • Blindness
  • Insulin-dependent diabetes
  • Macular degeneration
  • Severe sleep apnea

Participants will be randomly assigned to receive either a tailored light intervention or a placebo treatment at home for about 6 months. The intervention will provide daily stimulation by bluish-white (experimental) or yellow-white (control) light sources that are tuned to the sensitivity of the circadian system, which controls the human sleep-wake cycle. Researchers will determine if the intervention can improve sleep disturbances, inflammation, insulin sensitivity, glucose disposal, and cognition in people with MCI, mild Alzheimer's, or a related dementia.

Name City State Zip Status Primary Contact
Mount Sinai School of Medicine
New York New York 10029 Recruiting Christoph Buettner, MD, PhD

Rensselaer Polytechnic Institute

  • Icahn School of Medicine at Mount Sinai

Name Role Affiliation
Mariana G Figueiro, PhD Principal Investigator Rensselaer Polytechnic Institute

Name Phone Email
Christoph Buettner, MD, PhD 212-241-3425
Barbara Plitnick, RN 518-276-7166


Light, Metabolic Syndrome and Alzheimer's Disease: A Non-Pharmocological Approach